ArticleFrontiers in nutrition2025
Modulation of LPS-induced RAW 264.7 macrophages by
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gold nanoparticles (AuNPs) as emerging anti-inflammatory agents: mechanisms, therapeutic advances, and future directions-a systematic review and meta-analysis.Inflammopharmacology · 2026Pooled it
- Green synthesis, characterization, and anticancer activity of silver nanoparticles viaFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosynthesis of gold nanoparticles using medicinal plants has emerged as a promising strategy in nanobiotechnology due to their distinctive therapeutic attributes, including biological specificity, low cytotoxicity, and inherent biocompatibility. This study presents a straightforward phytosynthetic approach that eliminates requirements for additional stabilizing agents, demonstrating exceptional process simplicity and efficiency. The formation of Pk-AuNps was confirmed by UV-Vis spectroscopy with maximum absorbance at 540 nm. Comprehensive characterization through FE-TEM, EDX, and XRD revealed spherical morphology with face-centered cubic crystalline structure, while FTIR identified critical functional groups responsible for biological activity of Pk-AuNps. DPPH radical scavenging, ABTS inhibition, and ferric reducing power analysis further revealed that Pk-AuNps possess strong antioxidant activity. Cytocompatibility evaluations in RAW264.7 and A549 cell lines revealed excellent biosafety characteristics of Pk-AuNps, highlighting their biocompatibility for potential biomedical applications. Furthermore, the anti-inflammatory properties of Pk-AuNps in LPS-stimulated murine macrophages were also investigated. Notably, Pk-AuNps demonstrated potent anti-inflammatory effects in LPS-activated macrophages, significantly attenuating pro-inflammatory mediators through dual mechanisms: (1) Inhibition of NO and PGE2 production, and (2) Downregulation of iNOS and COX-2 gene expression. These findings indicate that Pk-AuNps show promise as functional food ingredients, demonstrating multifunctional bioactive properties to developing anti-inflammatory nutraceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.